ICLR
vs
S&P 500

Over the past 5 years, ICLR has underperformed S&P 500, delivering a return of 25% compared to the S&P 500's 83% growth.

Stocks Performance
ICLR vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
ICLR vs S&P 500

Performance Comparison
ICLR vs S&P 500

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
ICLR
ICON PLC
-2%
-27%
-34%
-22%
25%
299%
2 337%
S&P 500
Market Index
-2%
4%
7%
25%
83%
197%
400%

ICON PLC
Glance View

Market Cap
17.6B USD
Industry
Life Sciences Tools & Services

In the rapidly evolving landscape of global healthcare, ICON PLC stands out as a formidable player, seamlessly bridging the gap between innovative drug development and practical clinical application. Founded in Dublin, Ireland, ICON has grown into a multinational enterprise, deeply embedded in the research and development phases of various medical and biopharmaceutical companies. The company's core strength lies in its ability to offer comprehensive clinical trial services, encompassing every stage of drug development, from initial study design through to final data management and regulatory submissions. ICON's systematic approach not only shortens the timeline for bringing novel therapeutics to market but also ensures that these breakthroughs are both effective and safe, thereby garnering trust from clients ranging from burgeoning biotech startups to pharmaceutical giants. As a contract research organization (CRO), ICON operates within a business model designed to capitalize on the booming demand for outsourced R&D support. This model involves entering into strategic partnerships with clients to conduct all necessary research activities in exchange for fees, which can be structured through agreements for specific projects or longer-term collaborations. The company leverages its robust network, sophisticated technological platforms, and expert workforce to offer tailored solutions that optimize efficiency and accuracy. By doing so, ICON not only enhances its clients’ product pipelines but also secures a steady stream of revenue, further consolidated through repeat business and the expansion of its service repertoire to include emerging areas like digital health and real-world evidence. This disciplined and innovative approach propels ICON's growth, ensuring its financial health and reaffirming its integral role in driving medical advancement worldwide.

ICLR Intrinsic Value
304.69 USD
Undervaluation 30%
Intrinsic Value
Price

See Also

Back to Top